Genetic evidence for the role of transforming growth factor-β in atopic phenotypes

Abstract

New evidence in humans and mice supports a role for transforming growth factor-β (TGF-β) in the initiation and effector phases of allergic disease, as well as in consequent tissue dysfunction. This pleiotropic cytokine can affect T cell activation and differentiation and B cell immunoglobulin class switching following initial encounter with an allergen. TGF-β can also act on mast cells during an acute allergic episode to modulate the strength of the response, in addition to driving tissue remodeling following damage caused by an allergic attack. Accordingly, genetic disorders leading to altered TGF-β signaling can result in increased rates of allergic disease.

Fig. 1. Summary of the cellular mechanisms by which TGF-β may both promote and inhibit allergic outcomes.

T regulatory cell = Treg; Mast cell = Mast; B cell = B; T helper 2 cell = Th2; T helper 9 cell = Th9